Tesamorelin: A Stabilized GHRH Analog
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the GHRH(1-44) sequence with a trans-3-hexenoic acid modification at the N-terminus. This modification enhances metabolic stability while preserving full GHRHR agonist activity, making it a valuable research tool for studying GH-mediated biological processes.
Body Composition Research
Tesamorelin has been investigated in preclinical models for effects on body composition, particularly visceral adipose tissue. Research has examined whether GHRH-stimulated GH release influences lipid metabolism, adipocyte biology, and fat distribution patterns in animal models. These studies contribute to understanding the relationship between the GH/IGF-1 axis and metabolic regulation.
Comparison with Other GH Secretagogues
Compared with CJC-1295, tesamorelin retains the full GHRH(1-44) sequence versus CJC-1295's truncated (1-29) analog. Research comparing these compounds helps elucidate the structural requirements for optimal GHRHR activation and downstream GH release patterns.
Research Applications
Tesamorelin research extends beyond body composition to include hepatic steatosis models, cognitive function studies in aging animals, and cardiovascular parameter assessment. Its well-characterized GHRH agonism makes it a useful reference compound for GH axis research. ROEHN supports GH research with CJC-1295/Ipamorelin and complementary longevity compounds.
Research Disclaimer
This article is for educational and informational purposes only. All compounds discussed are intended strictly for in-vitro and preclinical research use. They are not intended for human consumption. Always consult published scientific literature and institutional review protocols before initiating any research program.